Q1 Earnings Estimate for NTLA Issued By HC Wainwright

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued on Wednesday, March 5th. HC Wainwright analyst M. Kapoor expects that the company will earn ($1.40) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q2 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.43) EPS and Q4 2026 earnings at ($1.17) EPS.

A number of other equities research analysts have also recently commented on the stock. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Monday. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Chardan Capital cut their price target on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a report on Friday, February 28th. BMO Capital Markets cut their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, January 10th. Finally, Morgan Stanley cut shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $56.00 to $11.00 in a report on Monday, January 27th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Stock Up 5.8 %

NASDAQ:NTLA opened at $9.90 on Thursday. The company’s 50 day moving average price is $10.64 and its 200-day moving average price is $15.28. Intellia Therapeutics has a 52 week low of $8.30 and a 52 week high of $32.00. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -1.82 and a beta of 1.97.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 29,000 shares of company stock worth $352,551. Company insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $43,177,000. Voloridge Investment Management LLC raised its position in shares of Intellia Therapeutics by 226.8% during the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock valued at $17,805,000 after purchasing an additional 1,059,751 shares during the period. Contrarius Group Holdings Ltd bought a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $11,798,000. Two Sigma Advisers LP raised its position in shares of Intellia Therapeutics by 94.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock valued at $23,300,000 after purchasing an additional 970,700 shares during the period. Finally, Two Sigma Investments LP raised its position in shares of Intellia Therapeutics by 88.1% during the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock valued at $21,498,000 after purchasing an additional 863,363 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.